ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

LUMO Lumos Pharma Inc

2,25
0,01 (0,45%)
Zuletzt aktualisiert: 18:08:14
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Lumos Pharma Inc LUMO NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,01 0,45% 2,25 18:08:14
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
2,24 2,24 2,25 2,24
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
07.6.202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.6.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.6.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.6.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.6.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.6.202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.6.202422:09EDGAR2Form 8-K - Current report
04.6.202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.6.202415:00GLOBELumos Pharma Announces New Analyses of Phase 2 OraGrowtH212..
20.5.202422:05GLOBELumos Pharma Announces Abstracts Accepted for Presentation..
15.5.202415:57EDGAR2Form 8-K - Current report
14.5.202422:15GLOBELumos Pharma Announces Positive End-of-Phase 2 Meeting with..
09.5.202420:51GLOBELumos Pharma to Report First Quarter 2024 Financial Results..
18.4.202422:05GLOBELumos Pharma Announces Abstracts Accepted for Presentation..
20.3.202413:00GLOBELumos Pharma Announces that the USPTO Has Granted Patent..
07.3.202422:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07.3.202422:44EDGAR2Form 8-K - Current report
07.3.202422:01GLOBELumos Pharma Reports Full Year 2023 Financial Results and..
26.2.202415:00GLOBELumos Pharma to Report Full Year 2023 Financial Results and..
07.2.202423:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.2.202422:02EDGAR2Form 144 - Report of proposed sale of securities
05.2.202423:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.2.202423:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.2.202423:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.2.202423:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.2.202423:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.2.202422:05GLOBELumos Pharma to Participate in Oppenheimer’s 34th Annual..
11.1.202401:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
04.1.202422:34EDGAR2Form 8-K - Current report
04.1.202422:05GLOBELumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to..
29.11.202322:30EDGAR2Form SC 13D/A - General statement of acquisition of..
21.11.202322:15GLOBELumos Pharma to Host Virtual Key Opinion Leader Webinar to..
20.11.202322:05GLOBELumos Pharma Announces Participation in the Piper Sandler..
15.11.202322:38EDGAR2Form 8-K - Current report
08.11.202300:24DJNLumos Pharma Shares Than Double After Hormone Deficiency..
07.11.202323:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.11.202322:42EDGAR2Form 8-K - Current report
07.11.202322:35GLOBELumos Pharma Reports Third Quarter 2023 Financial Results..
07.11.202322:08EDGAR2Form 8-K - Current report
07.11.202322:01GLOBELumos Pharma Announces Topline Data from Phase 2..
26.9.202322:34EDGAR2Form 8-K - Current report
26.9.202315:00GLOBELumos Pharma Announces New Data and Analysis of 15 Subjects..
14.9.202314:00GLOBELumos Pharma Announced Abstract Accepted for Oral..
07.9.202322:34GLOBELumos Pharma Announces Participation in Investor Conferences..
22.8.202315:00GLOBEIndependent Panel of Renowned Pediatric Endocrinologists to..
10.8.202315:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.8.202322:36EDGAR2Form 8-K - Current report
09.8.202322:01GLOBELumos Pharma Reports Second Quarter 2023 Financial Results,..
03.8.202322:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.8.202322:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..